Search results for "Lipoproteins."

showing 10 items of 492 documents

Accumulation of remnant-like particles in normolipidemic men with premature coronary artery disease

2003

lipoproteins remnant-like particles coronary artery disease
researchProduct

The Role of Fructose as a Cardiovascular Risk Factor: An Update

2022

There is increasing presence of fructose in food and drinks, and some evidence suggests that its higher consumption increases cardiovascular risk, although the mechanisms still remain not fully elucidated. Cardiovascular diseases (CVD) are still responsible for one-third of deaths worldwide, and therefore, their prevention should be assessed and managed comprehensively and not by the evaluation of individual risk factor components. Lifestyle risk factors for CVD include low degree of physical activity, high body mass index, alcohol consumption, smoking, and nutritional factors. Indeed, nutritional risk factors for CVD include unhealthy dietary behaviors, such as high intake of refined foods…

lipoproteinsCardiovascular disease Fructose Lipoproteins Nutrition Risk factorsnutritioncardiovascular diseaseEndocrinology Diabetes and MetabolismPerspectiverisk factorsMolecular BiologyBiochemistryMicrobiologyQR1-502fructose
researchProduct

Should we routinely measure low-density and high-density lipoprotein subclasses?

2009

Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) plasma populations are composed of heterogeneous subfractions that are different in size, density and protein/lipid content. There is increasing evidence that small, dense LDL particles are strongly associated with higher cardiovascular disease risk. Similarly, several studies have investigated whether smaller HDL particles are more protective than their larger counterparts and more recent findings suggest that small, dense HDL has significantly higher atheroprotective activity than larger L HDL. Yet, certain impairments of the protein/lipid content in small, dense HDL may decrease its antiatherogenic capacity or even induce p…

lipoproteinscardiovascular riskHDLlipids (amino acids peptides and proteins)subclassesaterosclerosiLDL
researchProduct

Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches

2013

Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk factor, since these particles can be associated with cardiovascular disease (CVD) independently of established risk factors, including plasma lipids. Obese subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL subclasses may be of clinical value in t…

lipoproteinsobesity treatmentobesitysmall dense low density lipoproteinlipid-lowering drugsanti-obesity drugslipids (amino acids peptides and proteins)metabolic syndrome
researchProduct

The significance of low-density lipoproteins size in vascular diseases

2006

Low density lipoproteins (LDL) comprise in humans two different main fractions: large, buoyant and small, dense particles. Small, dense LDL particles correlate negatively with plasma HDL levels and positively with plasma triglyceride concentrations and are associated with the metabolic syndrome and increased risk for cardiovascular disease. LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease (CHD). In addition, several studies have suggested that therapeutic modulation of specific LDL subclasses may be of great benefit in reducing the atherosclerotic risk. Therefore, LDL size measurement may be of potential value in the clinical ass…

low-density lipoproteins vascular diseases
researchProduct

Relative expression of cholesterol transport-related proteins and inflammation markers through the induction of 7-ketosterol-mediated stress in Caco-…

2013

Human diets contain sterol oxidation products that can induce cytotoxic effects, mainly caused by cholesterol oxides. However, phytosterol oxides effects have been less extensively investigated. This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells. These effects were linked to intracellular signaling pathways by using several inhibitors. Results showed 7-ketostigmasterol to have a greater proinflammatory potential than 7-ketocholesterol. In non-p…

media_common.quotation_subjectLipoproteinsInterleukin-1betaStigmasterolDown-RegulationInflammationToxicologyBradykininProinflammatory cytokineGene expressionmedicineHumansRNA MessengerATP Binding Cassette Transporter Subfamily G Member 5Acetyl-CoA C-AcetyltransferaseInternalizationKetocholesterolsmedia_commonInflammationbiologyTumor Necrosis Factor-alphaAnticholesteremic AgentsInterleukin-8Membrane ProteinsMembrane Transport ProteinsBiological TransportGeneral MedicineMetabolismSterolInterleukin-10Up-RegulationBiochemistryHMG-CoA reductasebiology.proteinTumor necrosis factor alphaATP-Binding Cassette TransportersAcyl Coenzyme Amedicine.symptomCaco-2 CellsBiomarkersFood ScienceFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct

Atherogenic dyslipidemia and oxidative stress: a new look

2009

Although results from in vitro studies and clinical trials demonstrate strong associations between oxidative stress and cardiovascular risk, to date still no convincing data are available to suggest that treatment with antioxidants might reduce vascular events. Oxidative modifications of low-density lipoproteins (LDL) represent an early stage of atherosclerosis, and small, dense LDL are more susceptible to oxidation than larger, more buoyant particles. Oxidized LDL are independent predictors of subclinical and clinical atherosclerosis. Recent studies suggested that novel therapeutic strategies may take into account the removal of such particles from circulation. Future research is required …

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthOxidative phosphorylation030204 cardiovascular system & hematology2704 Biochemistry (medical)medicine.disease_causeAtherogenic dyslipidemia oxidative stressCoronary artery disease03 medical and health sciences2737 Physiology (medical)0302 clinical medicinePhysiology (medical)Internal medicineHumansMedicineDyslipidemias030304 developmental biologySubclinical infectionchemistry.chemical_classification0303 health sciencesReactive oxygen speciesAtherogenic dyslipidemiabusiness.industryVascular diseaseBiochemistry (medical)Public Health Environmental and Occupational HealthAtherogenic dyslipidemia2739 Public Health Environmental and Occupational HealthGeneral MedicineAtherosclerosismedicine.disease3. Good healthLipoproteins LDLOxidative StressEndocrinologychemistrybusinessOxidized ldlOxidative stressTranslational Research
researchProduct

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

2008

Diabetic dyslipidemia is typically characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein cholesterol and a concomitant increase in atherogenic small dense low-density lipoproteins. Thiazolidindiones are able to lower the levels of fasting glucose and glycated hemoglobin significantly by improving insulin sensitivity, as well as improving some aspects of diabetic dyslipidemia: total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol tend to increase while triglycerides are generally decreased.This paper reviewed the effects of pioglitazone and rosiglitazone on atherogenic diabetic dyslipidemia, in particular on sma…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicine2736 Pharmacology (medical)HumansHypoglycemic AgentsPharmacology (medical)Clinical significancecardiovascular risk dense low-density lipoprotein diabetes low-density lipoprotein size pioglitazone rosiglitazone smallTriglyceridesDyslipidemiasPharmacologyAtherogenic dyslipidemiaPioglitazonebusiness.industryThiazolidindionesAtherogenic dyslipidemiaGeneral Medicinemedicine.diseaseLipoproteins LDLEndocrinology3004 PharmacologychemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)ThiazolidinedionesGlycated hemoglobinbusinessRosiglitazoneLipoproteins HDLPioglitazoneBiomarkersmedicine.drugLipoprotein
researchProduct

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges

2020

AbstractHemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting factor. The severity of bleeding and related complications is proportional to the amount of residual circulating functional factor. The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement. Advances in the engineering and manufacturing of clotting concentrates have led to the widespread availability of extended half-life products that reduced the number of intravenous infusions needed to achieve adequate trough levels. The…

medicine.medical_specialtyAcetylgalactosamineInjections SubcutaneousLipoproteinsHemorrhage030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedHemophilia AHemophilia BSeverity of Illness IndexDisease courseFactor IX03 medical and health sciencesRoute of administrationLife Expectancy0302 clinical medicineAntibodies BispecificmedicineHumansRNA Small InterferingInfusions IntravenousIntensive care medicineFactor IXClotting factorClinical Trials as TopicFactor VIIICoagulantsbusiness.industryGenetic TherapyHematologyIntravenous InfusionsHistory 20th CenturyBlood Coagulation FactorsLaboratoriesbusiness030215 immunologymedicine.drugHämostaseologie
researchProduct

Moderate consumption of beer reduces liver triglycerides and aortic cholesterol deposit in LDLr-/- apoB100/100 mice.

2006

This study was designed to address the effects of a moderate consumption of beer on serum and liver lipid parameters and on the development of aortic lesions in a mouse model associated with a human atherogenic lipoprotein profile. LDLr(-/-) apoB(100/100) mice received each day during 12 weeks either water, mild beer (0.570g of ethanol/kg of body weight) or ethanol-free beer in a single pure dose. Serum and liver lipid parameters were analyzed and atherosclerotic lesions were estimated in heart and aorta through their total cholesterol content. mRNA levels of enzymes and receptors involved in lipoprotein uptake, in fatty acid esterification and oxidation, and in reverse cholesterol transpor…

medicine.medical_specialtyApolipoprotein BAlcohol DrinkingCholesterol VLDLAortic DiseasesPalmitatesDown-RegulationAorta ThoracicMitochondria LiverPolymerase Chain ReactionPhosphatidylcholine-Sterol O-Acyltransferasechemistry.chemical_compoundMiceInternal medicinemedicineAnimalsRNA MessengerScavenger receptorChromatography High Pressure LiquidTriglyceridesApolipoproteins BbiologyTriglycerideCholesterolReverse cholesterol transportCholesterol HDLfood and beveragesBeerLipoprotein(a)Cholesterol LDLScavenger Receptors Class BAtherosclerosisMice Inbred C57BLEndocrinologychemistryLiverReceptors LDLLDL receptorbehavior and behavior mechanismsbiology.proteinlipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineOxidation-ReductionLipoproteinSterol Regulatory Element Binding Protein 2Atherosclerosis
researchProduct